Navigation Links
Southampton scientists begin Phase II patient trial for new asthma treatment
Date:4/8/2010

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

An increase in the frequency of asthma attacks (also known as 'exacerbations') is commonly triggered by cold or flu viruses because the lungs of patients with the condition are unable to mount the strong immune response that normally protects healthy airways.

When the infection spreads from the nose to the lungs it also causes inflammation which leads to such exacerbations.

A successful treatment to prevent virus-triggered asthma exacerbations would reduce the number of asthma patients suffering increased frequency of attacks and subsequently potentially life-threatening deterioration of lung function, thereby greatly reducing emergency admissions to hospital.

Professor Ratko Djukanovic, a clinical respiratory specialist at the University's School of Medicine and Southampton University Hospitals NHS Trust and Director of the Southampton Respiratory Biomedical Research Unit, explains: "When common cold or flu viruses spread from the nose and throat to the chest of asthma patients, they can cause a rapid deterioration in their health. Our scientists in Southampton, led by the team of Professor Donna Davies, have found in laboratory-based tests that the lungs are able to protect themselves when the protein interferon beta is introduced.

"If the drug works as we hope it will, it could significantly improve the quality of life for these patients and lessen the number of patients admitted to hospital. However, it is important to stress that there are a number of stages before the drug could be made available to the public.

"We are particularly pleased to have been joined in this clinical trial by other lead asthma centres in the UK which have similar biomedical research units funded by the National Institute for Health Research."

Over the next 9 - 15 months, asthma patients taking part in the study who visit the Biomedical Research Unit at Southampton General Hospital will be given either interferon beta or a placebo by inhalation, when they develop cold or flu symptoms.

The results will be used to determine if inhaled interferon beta is a viable treatment for virus-triggered asthma symptoms.

Scientists have already established that the drug was well tolerated in an earlier Phase I trial in asthma patients and that anti-viral defences were activated.

Richard Marsden, CEO of Synairgen, comments: "We are delighted to be starting this pivotal study. If these tests are successful it could lead to a new treatment being on the market in four years or so. This is very important research and showcases the best of British clinical science and interaction between industry and academic researchers."

Once the study has begun in Southampton, it will be extended to other clinical trial sites around the UK.


'/>"/>

Contact: Sophie Docker
S.Docker@soton.ac.uk
44-023-805-98933
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientists find out why living things are the size they are -- and none other
2. Scientists: Soccer improves health, fitness and social abilities
3. Pan-Asian hub for life scientists to open in Suzhou, China, on Monday, April 6
4. Scientists Find Clues to How the Body Fights Off HIV
5. Caltech scientists uncover structure of key protein in common HIV subgroup
6. Start spreading the news: NYU scientists find therapeutic target to stop cancer metastases
7. Scientists Tweak Subjects Brains to Alter Their Moral Choices
8. Scientists in hot pursuit of first new drug for global killer in 50 years
9. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
10. Anti-obesity drugs unlikely to provide lasting benefit according to scientists
11. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner ... in Frederick, MD. Judy says, “I am passionate about sharing Reiki as a ... very difficult and challenging time.” , A Certified Medical Reiki™ Master trained by ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The IoT (Internet ... WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... the IoT will have a value anywhere from $4 trillion to $11 trillion dollars ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 23, 2017  Mirabilis Medical, a ... for non-invasive surgery, announced today CE Mark authorization ... of uterine fibroids throughout the European Union.  The ... from the US Food and Drug Administration to ... in the United States.  The Mirabilis System combines ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... revitalizes efforts to develop sutezolid as effective response to ... Day, TB Alliance and the Medicines Patent Pool (MPP) ... sutezolid, an antibiotic drug candidate which demonstrated encouraging results ... of sutezolid in combination with other TB drugs and ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... CAGR of around 6.9% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
Breaking Medicine Technology: